Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Fig. 2 | BMC Cancer

Fig. 2

From: Homoharringtonine interacts synergistically with bortezomib in NHL cells through MCL-1 and NOXA-dependent mechanisms

Fig. 2

Co-treatment with HHT and bortezomib synergistically induces cell death in mantle cell lymphoma, and primary patient specimens, but not normal CD34+ bone marrow cells. a Granta-519, Jeko-1, JVM, NCEB, Mino cells were exposed to HHT (10, 20, 15, 15, 15 nmol/L respectively) and bortezomib (2.5, 3.5, 2.5, 2.5, 3 nmol/L respectively) alone or in combination for 48 h, after which cell death was assessed by 7-AAD. **p < 0.01, significantly greater than values for single agent treatment. b Jeko cells were exposed to the indicated concentration of HHT in the presence or absence of bortezomib for 48 h after which cell death was assessed by 7-AAD. **p < 0.01, significantly greater than values for single agent treatment. c Jeko-1 cells were treated with a range of HHT and bortezomib concentrations. At the end of this period, the percentage of 7AAD+ cells was determined by flow cytometry. CI values less than 1.0 reflect synergistic interactions. d Jeko-1 cells were treated with a range of HHT and bortezomib concentrations administered at a fixed ratio. The percentage of cell death was determined by monitoring 7AAD+ cells at 48 h. CI values were determined in relation to the fractional effect by using Calcusyn software. CI values less than 1.0 correspond to synergistic interactions. e Mononuclear peripheral blood cells from a primary double-hit DLBCL (pt#1) and a NHL follicular (pt#2) lymphoma were exposed to HHT (15–20 nmol/L) or bortezomib (4 nmol/L) individually in combination for 48 h, after which the percentage of apoptotic cells was determined by annexin V/PI (*p < 0.05, significantly greater than values for single-agent treatment). f Mononuclear cord blood cells were isolated and exposed to HHT (20 nmol/L) or bortezomib 5 nmol/L individually or in combination for 48 h, after which viable (non-apoptotic) CD34+ cells was determined by annexin V/PI positivity. P values for the combination were > 0.05, not significantly different compared to values for either agent alone

Back to article page